Che Torry, DO
Interventional Pain Medicine · Newport News, VANPI 1326402116
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.6%), food and beverage and grants — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $12,353 and has fallen 63.7% since, to $4,486 in 2025. Among interventional pain medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $104.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$35K
- Boston Scientific$6K
- Abbott$3K
- Si-bone, Inc.$2K
- Collegium Pharmaceutical, Inc.$825
- Globus Medical$573
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$1,0502%
- Grants$11,25023%
- Travel & lodging$18,94640%
- Food & beverage$16,52635%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 276 | $35,301 |
| Boston Scientific | 34 | $5,766 |
| Abbott | 27 | $2,570 |
| Si-bone, Inc. | 20 | $1,711 |
| Collegium Pharmaceutical, Inc. | 49 | $825 |
| Globus Medical | 7 | $573 |
| Nevro Corp. | 5 | $263 |
| Tersera Therapeutics LLC | 12 | $256 |
| Electronic Waveform Lab, Inc. | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $112 |
| Bioventus LLC | 2 | $77 |
| Fidia Pharma USA Inc. | 3 | $62 |
| Curonix LLC | 1 | $41 |
| Averitas Pharma Inc. | 2 | $38 |
| Corcept Therapeutics | 1 | $29 |
| Tonix Medicines, Inc. | 1 | $24 |
| Painteq LLC | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Avanos Medical | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$11,825
- SYNCHROMEDII$5,282
- INTELLIS ADAPTIVESTIM$3,920
- INTELLIS$3,528
- KYPHON EXPRESS II KYPHOPAK TRAY$2,210
- PROCLAIM$1,987
- OSTEOCOOL RF ABLATION SYSTEM$1,425
- IFUSE IMPLANT SYSTEM$831
- VANTA ADAPTIVESTIM$713
- Senza$551
- INCEPTIV$378
- WaveWriter Alpha Prime 16$284
- Accurian$146
- ITREL$146
- GENERAL PAIN MANAGEMENT$104
How this compares
$47,878 in reported general payments places this provider in the 95th percentile of 52 interventional pain medicine providers in Virginia.
See all interventional pain medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 31 | $32,772 |
| Xtampza ErOxycodone Myristate | 34 | $20,282 |
| Buprenorphine | 49 | $10,831 |
| BelbucaBuprenorphine Hcl | 21 | $10,409 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 216 | $6,818 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 253 | $6,589 |
| LyricaPregabalin | 11 | $5,965 |
| Pregabalin | 100 | $4,780 |
| Amitriptyline Hcl | 444 | $4,544 |
| Gabapentin | 231 | $3,654 |
| Fentanyl | 12 | $2,991 |
| Lidocaine | 33 | $2,890 |
| Methocarbamol | 157 | $2,053 |
| Diclofenac Sodium | 71 | $2,041 |
| Tramadol Hcl | 120 | $1,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er, Belbuca | $825 | $63,46386 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $22 | $11,87069 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 52 interventional pain medicine providers in Virginia.
Other interventional pain medicine in Newport News
- Raj SurejaNewport News$23K
- Jenny AndrusNewport News$4K
- Ketan PatelHaymarket$133K
- Niteesh BhararaReston$25K
- Sassan HassassianManassas$24K
- Benjamin SeemanRichmond$21K
- Alok GopalWinchester$16K
- Jacob LeeWinchester$14K
- Yaoming GuRichmond$13K
- Rae DavisLansdowne$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.